CELESTONE SOLUSPAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CELESTONE SOLUSPAN (CELESTONE SOLUSPAN).
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing immune cell activity.
| Metabolism | Hepatic via CYP3A4; primarily metabolized to inactive metabolites. |
| Excretion | Renal: ~65% as metabolites and unchanged drug; biliary/fecal: ~20%; remainder via other pathways. |
| Half-life | Plasma terminal half-life: betamethasone phosphate ~3-5 hours; betamethasone acetate ~6-8 hours. Clinical duration extended due to ester hydrolysis and depot effect (up to 7-14 days for IM injection). |
| Protein binding | ~64% primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd ~0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | IM: 100% (complete absorption). Oral: not applicable (injectable only). Intra-articular: effectively 100% locally; systemic bioavailability varies. |
| Onset of Action | IM: betamethasone phosphate within 1-2 hours; betamethasone acetate within 6-12 hours. Intra-articular/soft tissue: within 12-24 hours. |
| Duration of Action | IM: 7-14 days due to acetate microcrystals providing prolonged release. Intra-articular: 7-21 days, depending on joint size and pathology. |
| Molecular Weight | 392.5 |
1-2 mL (6-12 mg/mL betamethasone acetate and betamethasone sodium phosphate) intramuscularly or intralesionally, repeat every 1-4 weeks as needed.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution in severe renal disease due to fluid retention risk. |
| Liver impairment | No specific dose adjustment for Child-Pugh categories; monitor for increased corticosteroid effects in severe hepatic impairment. |
| Pediatric use | 0.02-0.3 mg/kg/day betamethasone equivalent intramuscularly or intralesionally, divided every 12-24 hours; duration as short as possible. |
| Geriatric use | Start at low end of dosing range; monitor for hyperglycemia, osteoporosis, and fluid retention; use minimal effective dose and duration. |
| 1st trimester | Betamethasone is a corticosteroid with teratogenic potential in animal studies. Use only if clearly needed; risk of cleft palate at doses above replacement. Monitor for adrenal suppression in mother. |
| 2nd trimester | Corticosteroids may cause fetal growth restriction with prolonged use. Short-term use for fetal lung maturity is established but benefits and risks must be weighed. |
| 3rd trimester | Use for fetal lung maturity; single course of betamethasone is standard. Avoid multiple courses due to potential for fetal growth restriction and adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for CELESTONE SOLUSPAN (CELESTONE SOLUSPAN).
| Placental transfer | Betamethasone crosses the placenta efficiently; biotransformation to the active metabolite in the placenta is limited. Fetal exposure is significant with maternal administration. |
| Breastfeeding | Betamethasone is excreted into breast milk but therapeutic doses are unlikely to cause adverse effects in the infant. Consider maternal dose and duration; monitor for adrenal suppression in the infant if chronic high doses are used. |
■ FDA Black Box Warning
Avoid intra-articular injection into unstable joints, infected areas, or near nerves. Not for intravenous use.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to betamethasone or any componentAdministration of live virus vaccinesIdiopathic thrombocytopenic purpura (IM use)
| Precautions | Increased risk of infection, adrenal suppression, osteoporosis, cataracts, glaucoma, and gastrointestinal perforation. Monitor for Cushing's syndrome with prolonged use. |
| Food/Dietary | Avoid high-sodium foods to reduce fluid retention and edema. Limit potassium-rich foods if hypokalemia is a concern. Grapefruit and grapefruit juice may increase systemic corticosteroid levels; use with caution. Alcohol consumption may increase risk of gastrointestinal irritation and ulcers. |
Loading safety data…
| Lactation Rating | L2 (probably compatible) |
| Teratogenic Risk | First trimester: Increased risk of oral clefts (odds ratio ~1.3-3.4). Second/third trimesters: Associated with fetal adrenal suppression, intrauterine growth restriction, and premature birth. Chronic use: Risk of cataracts, osteoporosis, and hypothalamic-pituitary-adrenal axis suppression in neonate. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Serial fetal ultrasound for growth restriction. Assess fetal adrenal suppression with neonatal evaluation. In preterm labor, use only if benefit outweighs risk; avoid prolonged therapy. |
| Fertility Effects | May impair fertility by disrupting ovulatory cycles due to suppression of gonadotropins. Chronic use may cause iatrogenic Cushing's syndrome and hypothalamic-pituitary-adrenal axis suppression, potentially reversible upon discontinuation. |
| Clinical Pearls | CELESTONE SOLUSPAN (betamethasone sodium phosphate and betamethasone acetate) is a dual-component injectable corticosteroid. The sodium phosphate component provides rapid onset (1-3 hours) while the acetate component offers sustained release (1-2 weeks). Avoid intra-articular injection in unstable joints or infected sites. Use cautious dose tapering to avoid adrenal insufficiency. Not for IV or epidural use. Monitor for signs of infection suppression. |
| Patient Advice | Do not discontinue suddenly without medical advice. · Report any signs of infection (fever, sore throat) or unusual bruising. · Avoid live vaccines during therapy. · Notify your doctor if you have diabetes, hypertension, or history of tuberculosis. · This injection is for local effect; systemic effects may occur with repeat doses. |